What is APHP-002 used for?

APHP-002 is indicated for Type 2 diabetes.

APHP-002 is developed by Aphaia Pharma US LLC.

What are the side effects of APHP-002?

Common side effects include Nausea, Diarrhea, Vomiting.

Last reviewed 2026-04-23 · How we verify

APHP-002

Aphaia Pharma US LLC · Phase 2 active Small molecule

APHP-002 is a small molecule that targets the SGLT2 receptor.

APHP-002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	APHP-002
Sponsor	Aphaia Pharma US LLC
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 2

Mechanism of action

By inhibiting SGLT2, APHP-002 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results